Sutro Biopharma Participated in a Clinical Trial, “Egg-Derived Anti-SARS-CoV-2 Immunoglobulin Y (IgY) With Broad Variant Activity as Intranasal Prophylaxis Against COVID-19” Published by Frontiers in Immunology | Sutro Biopharma, Inc.

Sutro Biopharma Participated in a Clinical Trial, “Egg-Derived Anti-SARS-CoV-2 Immunoglobulin Y (IgY) With Broad Variant Activity as Intranasal Prophylaxis Against COVID-19” Published by Frontiers in Immunology

Jun 2, 2022

Clinical Trial Article

Egg-Derived Anti-SARS-CoV-2 Immunoglobulin Y (IgY) With Broad Variant Activity as Intranasal Prophylaxis Against COVID-19

https://www.frontiersin.org/articles/10.3389/fimmu.2022.899617/full

Frontiers in Immunology

Published: 01 June 2022